Treatment News : Gilead and Tibotec’s Combo HIV Drug Is Back on Track

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
E-newsletters
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join
Username:
Password:

Back to home » Treatment News » February 2011

Most Popular Links
Most Popular Lessons

The HIV Life Cycle

Shingles

Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

15 Years Ago In POZ


More Treatment News

Click here for more news

Have news about HIV? Send press releases, news tips and other announcements to news@poz.com.


emailprint

February 11, 2011

Gilead and Tibotec’s Combo HIV Drug Is Back on Track

Gilead announced that it is back on track with the approval process for the combination antiretroviral (ARV) pill it is developing in partnership with Tibotec, having refiled its New Drug Application (NDA) with the U.S. Food and Drug Administration (FDA). The FDA rejected the original NDA in a letter dated January 25 over concerns about impurities found during test-batches of the new pill.

Gilead initially filed for approval of the fixed-dose combination tablet—which combines Tibotec’s rilpivirine (TMC278) with Gilead’s Truvada (tenofovir plus emtricitabine)—in November 2010. However, the FDA sent Gilead a “refuse to file” notification in late January, asking the company to provide further information about how the company came to determine what constitutes acceptable levels of “degradents” of emtricitabine that occurred while manufacturing the new combo pill. Drugs sometimes contain trace impurities, and it is the manufacturer’s responsibility to prove to the FDA the maximum levels of the impurity that the drug can contain and still remain safe and effective for people who take it. These data were included in the new filing Gilead just sent to the FDA.

Gilead reported in January that the refusal to file meant that when it resubmitted the application the drug could still receive priority review, which can shave months off the approval process. The FDA now has two months to decide whether the application is sufficient to proceed with the approval process—and to set a target date for approval.

Search: Gilead, Tibotec, combo pill, fixed-dose combination, rilpivirine, TMC278, new drug application, FDA, Truvada, tenofovir, emtricitabine


Scroll down to comment on this story.



Name:

(will display; 2-50 characters)

Email:

(will NOT display)

City:

(will display; optional)

Comment (500 characters left):

(Note: The POZ team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules



Show comments (0 total)

 
[Go to top]


Join POZ Facebook Twitter Google+ MySpace YouTube Tumblr Flickr
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar


    dversescott
    Baltimore
    Maryland


    july8th69
    brooklyn
    New York


    Heartland4now
    Tacoma
    Washington

This could be you!
Click here to join POZ Personals!
Ask POZ Pharmacist

Talk to Us
Poll
Will decriminalizing injection drug use help end the global HIV epidemic?
Yes
No

Survey
PrEP Course

more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.